Researchers evaluated Pfizer-BioNTech’s BNT162b2 messenger ribonucleic acid (mRNA) vaccine effectiveness (VE) against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infections among the pediatric and adolescent population of Qatar.
Researchers evaluated Pfizer-BioNTech’s BNT162b2 messenger ribonucleic acid (mRNA) vaccine effectiveness (VE) against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infections among the pediatric and adolescent population of Qatar.
Comments